MedTrace Logo

B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)

NCT03020498 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2018-06-06

Study results available
· View outcomes & findings →

Summary

In this exploratory study, investigators will be looking at immune response differences between age groups and between the two different influenza vaccines given to identical twins, vaccine-naive young adults and elderly participants.

Conditions

Interventions

BIOLOGICAL

Fluzone

Influenza Virus Vaccine Suspension for Intramuscular Injection

BIOLOGICAL

FluMist

Influenza Virus Vaccine Live, Intranasal Intranasal Spray

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Cornelia Dekker, MD · Stanford University

  • Harry Greenberg, MD · Stanford University

  • Stephen Quake, PhD · Stanford University

  • Xiaosong He, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-12-31
Completion
2011-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03020498 on ClinicalTrials.gov